Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
about
Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutationsCurrent status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapyPD-1/PD-L1 blockades in non-small-cell lung cancer therapyImmune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer TreatmentPD-1 and its ligands are important immune checkpoints in cancerCheckpoint inhibitors in lung cancer: latest developments and clinical potentialClinical Research Progress of Anti PD-1/PD-L1 Monoclonal Antibody in the Treatment of Lung CancerProgrammed death-ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor.PD-L1 expression associated with better response to EGFR tyrosine kinase inhibitorsThe association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIsImmune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung CancerInhibition of eEF-2 kinase sensitizes human nasopharyngeal carcinoma cells to lapatinib-induced apoptosis through the Src and Erk pathways.Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer.PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survivalRRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report.Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patientsPD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutationsProgrammed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?Discovery of Gene Sources for Economic Traits in Hanwoo by Whole-genome ResequencingTemporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer.Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.Induction of Patient-Derived Xenograft Formation and Clinical Significance of Programmed Cell Death Ligand 1 (PD-L1) in Lung Cancer Patients.Possible Noninvasive Biomarker of Eosinophilic Esophagitis: Clinical and Experimental Evidence.Induction of PD-L1 expression by epidermal growth factor receptor-mediated signaling in esophageal squamous cell carcinoma.Impact of gefitinib in early stage treatment on circulating cytokines and lymphocytes for patients with advanced non-small cell lung cancer.Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy.Afatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent progress.Update on afatinib-based combination regimens for the treatment of EGFR mutation-positive non-small-cell lung cancer.Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.Identifying Regulatory Posttranslational Modifications of PD-L1: A Focus on Monoubiquitinaton.Immune checkpoint therapy for non-small-cell lung cancer: an update.Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.Immunogenomics: using genomics to personalize cancer immunotherapy.Targeting EGFR mutation in non-small-cell lung cancer: challenges and future perspectives.Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategy.Platelet-lymphocyte ratio is an independent prognostic factor in patients with ALK-positive non-small-cell lung cancer.Resistance to Therapy.EGFR TKI combination with immunotherapy in non-small cell lung cancer.Mechanisms of Resistance to Immune Checkpoint Antibodies.Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response.
P2860
Q26744339-0FAADB51-1591-4D36-988A-9A3C76309DCBQ26745516-1EAC6314-1DC5-4E27-A003-6B43B200B3EAQ26765024-45622DB6-C9BC-43FF-80F4-82D151EF77D2Q28069424-BC5D5F44-5430-4C51-B0E1-00B30DB910DDQ28069485-3884853D-0DD7-4A84-919E-D30224F46BAEQ28076467-55A0C23C-AFD5-4301-9E47-2FDC2DD366D9Q28084766-471D54EB-056E-49C2-81B4-61CF073EEC79Q33607407-4A717DA5-8AA7-4614-B709-89562BD10A18Q35824122-61BA762A-452B-4CF9-AA2B-F5F82E59068FQ35987305-100AE0E5-4616-4C32-9E8D-A3CAAD70ED70Q36088496-F21B5FAE-0469-428C-8073-B051712EEF8CQ36166739-9D5E80A9-0229-4210-88C7-3A3DD0CAC34FQ36517199-8D6E2D84-B4AB-4A38-AB73-CB4F04D10FE3Q36545054-493FE5ED-99A7-4006-8D41-CE96C2E5953FQ36566472-B7513F60-55B6-49E4-AC56-2D97BE8512B4Q36821248-7A058DC6-7F9C-467D-9F8D-1921C8748706Q37013280-382B41D1-DEF4-4F3A-BCD2-6145755611C1Q37094056-1F30995C-2810-4C44-9A2F-CD3B52C97892Q37215322-3DC06ED3-BE2C-4698-8B55-53C1C0B6EDC1Q37281262-BD86CA64-AA03-4BD7-B665-272A01ED5FD2Q37362623-3D15A350-D63B-4988-9104-A2533CD6D924Q37381288-E546A58B-A273-4B41-AB84-7DF49E762170Q37449004-7E90669F-5607-4C8C-B0B6-5D907372634FQ37650062-4E57464C-A986-48B0-9FCB-A850BAAC8726Q37669516-90191311-315C-4F0E-90D7-466C217B54C1Q37741143-964AE8D9-0204-4DC8-B72E-B4171E799A3AQ38646686-97227C12-9520-4A97-AD89-4C244603FA26Q38665706-B2AE6870-5C14-468B-8796-DDCCA9CA1EE7Q38700735-F9912E10-7071-41A4-BF38-C3137131B102Q38711525-B2D04A14-7E93-4731-A728-24FF408A6476Q38727542-8F67C348-6FC4-44F2-8FE7-A9CD3526250FQ38746756-2B56D394-3E2E-4380-84DC-8588F13DB093Q38772744-C2C28CBC-9AEB-4AF9-9E68-2E8538C0FAA7Q38821624-207C05E7-C637-42AE-AE4C-E62EB6A8F4FBQ38827684-31B0B271-E499-4807-BA0F-F0C0AB8A65AFQ38831513-60C2517B-14BE-4278-A633-63CEBD6F0F05Q38930367-5A534885-54F6-4B6B-834C-C72D1B5E0DFBQ39167752-185605B0-FF5D-47FB-BA7D-8CBECF6B4E0DQ39185608-4466EEAD-A9E7-4E17-9D1C-C3A3FB4BCD3BQ39194722-9CA3FF98-F5AB-4AF2-BFBA-5BFCE7344EB5
P2860
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Upregulation of PD-L1 by EGFR ...... C Patients with EGFR Mutation.
@en
type
label
Upregulation of PD-L1 by EGFR ...... C Patients with EGFR Mutation.
@en
prefLabel
Upregulation of PD-L1 by EGFR ...... C Patients with EGFR Mutation.
@en
P2093
P1476
Upregulation of PD-L1 by EGFR ...... C Patients with EGFR Mutation.
@en
P2093
Jianhua Zhan
Shaodong Hong
Shiyang Kang
Wenfeng Fang
Xianping Yi
P304
P356
10.1097/JTO.0000000000000500
P577
2015-06-01T00:00:00Z